Skip to content

Pericardial Histopathology and COVID-19 Seropositivity

Pericardial Histopathology and COVID-19 Seropositivity in Adult Patients Undergoing First-Time Coronary Artery Bypass Grafting: A Prospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06952179
Enrollment
93
Registered
2025-04-30
Start date
2023-02-01
Completion date
2024-06-01
Last updated
2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Inflammatory Response, Pericardial Disease

Brief summary

This prospective study aims to investigate the association between pericardial histopathologic inflammation grades (acute, chronic, or absent) and COVID-19 seropositivity in adult patients undergoing first-time isolated coronary artery bypass grafting (CABG). Pericardial tissue samples were collected during surgery and evaluated histopathologically, while preoperative COVID-19 serological testing was performed. The primary outcome is to determine whether COVID-19 seropositivity is associated with the severity of pericardial inflammation. Patients with prior cardiac surgery, active COVID-19 infection, systemic inflammatory diseases, chronic immunosuppressive therapy, or malignancy were excluded from the study.

Interventions

None listed

Sponsors

Samsun University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years

Inclusion criteria

* Age ≥20 years * Undergoing first-time isolated coronary artery bypass grafting (CABG) * Availability of pericardial tissue sample for histopathological analysis * Preoperative COVID-19 serological testing performed * Written informed consent obtained

Exclusion criteria

* Previous history of cardiac surgery (e.g., prior CABG, valve surgery) * Concomitant cardiac procedures during the same operation (e.g., valve repair, aortic surgery) * Active COVID-19 infection at the time of surgery (positive PCR test) * Known autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis) * Chronic immunosuppressive therapy (e.g., steroids, biologics) * Known malignancy at the time of surgery Insufficient or inadequate pericardial tissue sample for histopathological assessment

Design outcomes

Primary

MeasureTime frameDescription
Pericardial inflammation histopatalogical evaluationup to 1 yearprospective evaluation of the relationship between pericardial inflammation grade (0: absent, 1: mild, 2: moderate, 3: severe) and COVID-19 seropositivity in adult patients undergoing first-time coronary artery bypass grafting. The primary outcome of this study is to investigate the association between pericardial inflammation grade, as determined by histopathological evaluation (categorized as acute, chronic, or absent inflammation), and COVID-19 seropositivity in adult patients undergoing first-time coronary artery bypass grafting.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026